Uveitic GlaucomaNCT02765308
Aqueous Humor Dynamics and Hypertensive Uveitis
An observational study of Uveitic Glaucoma and Anterior Uveitis, run by Guy's and St Thomas' NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
Uveitis is a disease that affects over 2 million people around the globe, and can ultimately lead to blindness. The proportion of patients with uveitis who become blind has not been reduced over the past 30 years, and this is therefore an area that demands further research. Read more about this study
- Who is it for?
- Ages 18 to 90 yearsHealthy volunteers can take part
- Conditions the study is for
- Uveitic Glaucoma, Anterior Uveitis
- How many people
- 94 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Aug 2013to Dec 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: 30 patients will be included from each of these three group of patients: 1) recurrent (> 5 attacks) idiopathic acute anterior uveitic with raised intraocular pressure; 2) recurrent (> 5 attacks) idiopathic acute anterior uveitic without raised intraocular pressure; 3) healthy age matched volunteers as controls.
Who may be able to join
- Patients with idiopathic recurrent anterior uveitis with or without raised IOP.
- Normal healthy subjects with no ocular problems (other than refractive error) and IOP at screening < 21mmHg.
- Age >18 years.
- Adequate cognitive function and ability to understand verbal and written information in English.
Who cannot join
- Other secondary glaucomas including pigment dispersion syndrome and pseudoexfoliation.
- Normotensive glaucoma.
- Primary angle closure.
- Ocular trauma.
- Intraocular or keratorefractive surgery.
- Use of systemic medication that may affect aqueous humour production such as beta-blockers.
- A history of allergy or hypersensitivity to fluorescein.
- Any abnormalities preventing reliable IOP or fluorophotometric readings.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Guys and St Thomas NHS Foundation Trust
London, SE1 7EH
About this study
Official title: The Contribution of Altered Aqueous Dynamics in the Development of Raised Intraocular Pressure in Patients With Uveitis
Uveitis is a disease that affects over 2 million people around the globe, and can ultimately lead to blindness. The proportion of patients with uveitis who become blind has not been reduced over the past 30 years, and this is therefore an area that demands further research. One of the major causes of blindness in uveitic patients is the development of uveitic glaucoma, which occurs in 10-20% of uveitic eyes. This is likely to occur for reasons related to the uveitis itself, but can also be caused as a side effect of the corticosteroids used to treat uveitis. The raised IOP in uveitis is more difficult to treat than other types of glaucoma.
To enable more effective treatment of uveitic glaucoma, the investigators need to understand more clearly the mechanisms which underlie this process. The investigators therefore propose a study to examine the contribution of altered aqueous dynamics to the development of raised IOP in uveitis.
Read the detailed description
The investigators propose to undertake a cross-sectional observational study of patients with recurrent idiopathic acute anterior uveitis, to determine the relative contributions of altered aqueous production and drainage to the development of raised IOP in these patients.
Methods
Study Design A cross sectional observational study
Patient Selection All subjects attending the uveitis and glaucoma clinics at St Thomas' Hospital will be eligible to be included in the study if they fulfil the inclusion/exclusion criteria as below.
30 patients will be included from each of these three group of patients: 1) recurrent (> 5 attacks) idiopathic acute anterior uveitic with raised intraocular pressure; 2) recurrent (> 5 attacks) idiopathic acute anterior uveitic without raised intraocular pressure; 3) healthy age matched volunteers as controls. Patients on glaucoma treatment will be washed out for one month before measurement.
Examination Schedule and Methods
- Visual acuity: Visual acuity is measured before pupil dilation, tonometry, gonioscopy, or any other technique that could affect vision. Two different techniques are used to measure visual acuity, including Snellen and ETDRS visual acuity testing. Refraction is performed prior to formal measurement of visual acuity by either technique. Subjective Refraction: It is permissible to use a phoropter or trial frame to determine best-corrected Snellen visual acuity. The left eye is occluded first. An approximate beginning refraction may be determined by retinoscopy, automated refraction, or a subjective refraction from a prior visit. The sphere is refined first. The cylinder is then refined, first the axis followed by the power. Finally, the sphere is rechecked. The right eye is then occluded, and the procedure is repeated for the left eye. If the patient wears contact lenses and has glasses also, he or she is instructed not to wear the contact lenses on the day of the assessment. Patients unwilling to discontinue contact lens use after surgery will be excluded from the study. In the event that the patient either has no glasses or has forgotten the instructions and reported for the assessment wearing contact lenses, the contact lenses are removed and at least thirty minutes allowed to elapse before subjective refraction and visual acuity testing is performed. ETDRS Visual Acuity: The logmar visual acuity testing for the Uveitic Glaucoma study has been adapted from the Early Treatment of Diabetic Retinopathy (ETDRS) at 4 metres. The logmar visual acuity scale facilitates statistical analysis and simplifies quantification of acuity at various distances. The right eye is tested with ETDRS logmar chart 1, then the left eye is tested with ETDRS logmar chart 2. Each chart is hidden from view until the eye being examined is ready for testing. Snellen Visual Acuity: Snellen visual acuity may be measured using any standard visual acuity chart. The same type of chart must be used throughout the duration of the study. Standardized refraction is performed prior to Snellen visual acuity testing.
- Slit lamp biomicroscopy Examination of the anterior segment using slit lamp biomicroscopy will be performed. Slit lamp biomicroscopy may be performed with any commercially available instrument, and it is used in a standard fashion starting anteriorly and working posteriorly.
- Gonioscopy Gonioscopy is performed with the patient sitting at the slit lamp using either a Zeiss type four-mirror gonioprism or Goldmann single- or three-mirror lens.
- Pachymetry Central corneal thickness is measured with ultrasound pachymetry. The right eye is tested first. A drop of 0.5% proparacaine is instilled for anesthesia. The patient is asked to look straight ahead at a distant object or fixation target. The pachymeter probe is lined up with the center of the pupil and slowly advanced until it contacts the cornea. The probe is withdrawn when an audible signal is made indicating that a measurement has been recorded. The patient is instructed to blink. The procedure is repeated to obtain three separate readings, and the investigator records the measurements. After testing of the right eye is complete, the same technique is applied to testing of the left eye.
- Biometry A Carl Zeiss IOL Master will be used to carry out biometry and assess anterior chamber depth using A-scan ultrasound. This is a non-contact examination technique.
- Fundoscopy A dilated fundus examination is performed. After pupil dilation with appropriate mydriatics, the optic nerve and posterior pole are examined at the slit lamp using Volk 90 diopter, 78 diopter, or 60 diopter lens.
- Flurophotometry The night before (10 PM) the fluorophotometric scans, participants will self-administered 3 to 6 drops of fluorescein sodium 2% (Minims, Bausch\&Lomb, UK) topically into both eyes at 5 minutes interval depending on their age (age 25 years or younger, 5-6 drops; age 26 to 35 years, four drops; over 35 years of age, three drops). Fluorophotometry will be performed in both eyes using a scanning ocular fluorophotometer from 9AM to 12PM (FM-2, Fluorotron Master Ocular Fluorophotometer; OcuMetrics, Mountain View, California). The aqueous turnover protocol will be used to calculate the aqueous flow rate. Duplicate or triplicate scans will be collected and repeated at 1 hour intervals for 4 measurements to determine the aqueous flow rate (Ft). Following each set of scans, IOP will be measured using pneumatonometry (Model 30 Classic, Reichert Ophthalmic Instruments, Depew, New York). IOP will be recorded as the arithmetic mean of a total of 12 measurements per eye: 3 measurements every hour alternating between eyes.
- Tonography Tonographic outflow facility (C) will be performed using an electronic Schiøtz tonographer (Model 720, Berkeley Bioengineering Inc, USA) at 10AM. The facility of outflow will be calculated from the rate of decay of intraocular pressure in the supine position during application of a recording Schiøtz tonometer over a period of 4 minutes with a standard 5.5 gram weight. The "R" values of the curve at every 30-second time point will be manually entered into the McLaren tonography computer program. The program fits a second-degree polynomial by least squares to the nine data points and determines the best-fit values for time 0 and time 4 minutes by extrapolation. Uveoscleral outflow will be calculated using the Goldmann's equation with an assumed episcleral venous of 8, 9, 10 or 11 mmHg. Ft is the rate of aqueous humor formation, C is the tonographic facility of outflow, IOP is the intraocular pressure, Pv is the episcleral venous pressure and Fu is the uveoscleral outflow. Ft = C (IOP-Pv) +Fu Fu = Ft-C (IOP-Pv) Only one randomly (Excel random number generator) chosen eye per participant will be included in the data analysis when both eyes fulfilled the inclusion criteria.
- Visual fields Quantitative automated perimetry is performed using the Humphrey Field Analyzer. Visual field testing is performed before tonometry, gonioscopy, or any other technique that could affect vision. A visual field should be attempted in any eye that has sufficient vision to permit finger counting at two feet. Eyes with poor central vision may have an intact, off-center island of vision which may be measured with perimetry.
A 24-2 threshold test is performed in all patients using a size III white stimulus. Visual field testing may be performed with the Swedish Interactive Thresholding Algorithm (SITA) or full threshold strategy, but the same testing strategy must be used throughout the duration of the study. The pupil diameter should be 3 mm or greater before visual field testing is undertaken, and this may require pharmacologic dilation. Standardized refraction is performed to determine the patient's distance refraction and best-corrected visual acuity prior to visual field testing. The age appropriate plus lens is added to the distance refraction. Patient education is provided, and the instrument is set up for the test. The technician should monitor the patient during testing. Visual fields are performed preoperatively (within one month of enrollment in the study) and annually thereafter. Copies of all visual fields are faxed to the Statistical Coordinating Center for evaluation.
- Conditions
- Uveitic Glaucoma, Anterior Uveitis
- Keywords
- Uveitis, Glaucoma, Aqueous humor dynamics
- Medical subject headings
- Uveitis, Anterior, Uveitis, Glaucoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Healthy volunteers | healthy age matched with cases volunteers as controls | |
| Uveitis with raised IOP | Recurrent (> 5 attacks) idiopathic acute anterior uveitic with raised intraocular pressure | |
| Uveitis with with normal IOP | Recurrent (> 5 attacks) idiopathic acute anterior uveitic with normal intraocular pressure |
What is being measured
The primary outcome is the main question the study is designed to answer.
Facility of outflow
Tonographic outflow facility (C) will be performed using an electronic Schiøtz tonographer (Model 720, Berkeley Bioengineering Inc, USA) at 10AM
Measured: day 1 only (study completion)
Rate of aqueous flow (measured by fluorophotometry).
Fluorophotometry will be performed in both eyes using a scanning ocular fluorophotometer from 9AM to 12PM (FM-2, Fluorotron Master Ocular Fluorophotometer; OcuMetrics, Mountain View, California). The aqueous turnover protocol will be used to calculate the aqueous flow rate. Duplicate or triplicate scans will be collected and repeated at 1 hour intervals for 4 measurements to determine the aqueous flow rate (Ft).
Measured: Four times during the morning through day 1 only (study completion)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2016 (estimated)
- Study startAug 2013
- Primary completionDec 2016
- Study completionDec 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Uveitic GlaucomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 94 participants (actual)
Sponsor and investigators
- Lead sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- K Sheng l, MD, Principal investigator, Guy's and St Thomas NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02765308
- Sponsor's protocol ID
- 136787
- Status last verified
- Jul 2017
- First submitted
- 27 Apr 2016
- Last updated
- 1 Aug 2017
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No: No plans to share IPD
Publications
Ho H, Daas A, Ho J, Alaghband P, Galvis EA, de Antonio Ramirez A, Grassi P, Lim R, Lim KS. Intraocular pressure changes following topical ocular hypotensive medications washout. Br J Ophthalmol. 2021 Feb;105(2):205-209. doi: 10.1136/bjophthalmol-2019-315778. Epub 2020 Apr 10.
PubMed 32277009
Study at a glance
From the registry record, last updated by the sponsor on 1 Aug 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Contribution of Altered Aqueous Dynamics in the Development of Raised Intraocular Pressure in Patients With Uveitis
- ClinicalTrials.gov ID
- NCT02765308
- Acronym / sponsor ID
- 136787
- Conditions
- Uveitic Glaucoma, Anterior Uveitis
- Keywords
- Uveitis, Glaucoma, Aqueous humor dynamics
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 94 participants (actual)
- Lead sponsor
- Guy's and St Thomas' NHS Foundation TrustUniversity, hospital or other
- Study start
- Aug 2013
- Primary completion
- Dec 2016 (actual)
- Study completion
- Dec 2016 (actual)
- First posted
- 6 May 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Uveitis is a disease that affects over 2 million people around the globe, and can ultimately lead to blindness. The proportion of patients with uveitis who become blind has not been reduced over the past 30 years, and this is therefore an area that demands further research. One of the major causes of blindness in uveitic patients is the development of uveitic glaucoma, which occurs in 10-20% of uveitic eyes. This is likely to occur for reasons related to the uveitis itself, but can also be caused as a side effect of the corticosteroids used to treat uveitis. The raised IOP in uveitis is more difficult to treat than other types of glaucoma.
To enable more effective treatment of uveitic glaucoma, the investigators need to understand more clearly the mechanisms which underlie this process. The investigators therefore propose a study to examine the contribution of altered aqueous dynamics to the development of raised IOP in uveitis.
Detailed description
The investigators propose to undertake a cross-sectional observational study of patients with recurrent idiopathic acute anterior uveitis, to determine the relative contributions of altered aqueous production and drainage to the development of raised IOP in these patients.
Methods
Study Design A cross sectional observational study
Patient Selection All subjects attending the uveitis and glaucoma clinics at St Thomas' Hospital will be eligible to be included in the study if they fulfil the inclusion/exclusion criteria as below.
30 patients will be included from each of these three group of patients: 1) recurrent (> 5 attacks) idiopathic acute anterior uveitic with raised intraocular pressure; 2) recurrent (> 5 attacks) idiopathic acute anterior uveitic without raised intraocular pressure; 3) healthy age matched volunteers as controls. Patients on glaucoma treatment will be washed out for one month before measurement.
Examination Schedule and Methods
- Visual acuity: Visual acuity is measured before pupil dilation, tonometry, gonioscopy, or any other technique that could affect vision. Two different techniques are used to measure visual acuity, including Snellen and ETDRS visual acuity testing. Refraction is performed prior to formal measurement of visual acuity by either technique. Subjective Refraction: It is permissible to use a phoropter or trial frame to determine best-corrected Snellen visual acuity. The left eye is occluded first. An approximate beginning refraction may be determined by retinoscopy, automated refraction, or a subjective refraction from a prior visit. The sphere is refined first. The cylinder is then refined, first the axis followed by the power. Finally, the sphere is rechecked. The right eye is then occluded, and the procedure is repeated for the left eye. If the patient wears contact lenses and has glasses also, he or she is instructed not to wear the contact lenses on the day of the assessment. Patients unwilling to discontinue contact lens use after surgery will be excluded from the study. In the event that the patient either has no glasses or has forgotten the instructions and reported for the assessment wearing contact lenses, the contact lenses are removed and at least thirty minutes allowed to elapse before subjective refraction and visual acuity testing is performed. ETDRS Visual Acuity: The logmar visual acuity testing for the Uveitic Glaucoma study has been adapted from the Early Treatment of Diabetic Retinopathy (ETDRS) at 4 metres. The logmar visual acuity scale facilitates statistical analysis and simplifies quantification of acuity at various distances. The right eye is tested with ETDRS logmar chart 1, then the left eye is tested with ETDRS logmar chart 2. Each chart is hidden from view until the eye being examined is ready for testing. Snellen Visual Acuity: Snellen visual acuity may be measured using any standard visual acuity chart. The same type of chart must be used throughout the duration of the study. Standardized refraction is performed prior to Snellen visual acuity testing.
- Slit lamp biomicroscopy Examination of the anterior segment using slit lamp biomicroscopy will be performed. Slit lamp biomicroscopy may be performed with any commercially available instrument, and it is used in a standard fashion starting anteriorly and working posteriorly.
- Gonioscopy Gonioscopy is performed with the patient sitting at the slit lamp using either a Zeiss type four-mirror gonioprism or Goldmann single- or three-mirror lens.
- Pachymetry Central corneal thickness is measured with ultrasound pachymetry. The right eye is tested first. A drop of 0.5% proparacaine is instilled for anesthesia. The patient is asked to look straight ahead at a distant object or fixation target. The pachymeter probe is lined up with the center of the pupil and slowly advanced until it contacts the cornea. The probe is withdrawn when an audible signal is made indicating that a measurement has been recorded. The patient is instructed to blink. The procedure is repeated to obtain three separate readings, and the investigator records the measurements. After testing of the right eye is complete, the same technique is applied to testing of the left eye.
- Biometry A Carl Zeiss IOL Master will be used to carry out biometry and assess anterior chamber depth using A-scan ultrasound. This is a non-contact examination technique.
- Fundoscopy A dilated fundus examination is performed. After pupil dilation with appropriate mydriatics, the optic nerve and posterior pole are examined at the slit lamp using Volk 90 diopter, 78 diopter, or 60 diopter lens.
- Flurophotometry The night before (10 PM) the fluorophotometric scans, participants will self-administered 3 to 6 drops of fluorescein sodium 2% (Minims, Bausch\&Lomb, UK) topically into both eyes at 5 minutes interval depending on their age (age 25 years or younger, 5-6 drops; age 26 to 35 years, four drops; over 35 years of age, three drops). Fluorophotometry will be performed in both eyes using a scanning ocular fluorophotometer from 9AM to 12PM (FM-2, Fluorotron Master Ocular Fluorophotometer; OcuMetrics, Mountain View, California). The aqueous turnover protocol will be used to calculate the aqueous flow rate. Duplicate or triplicate scans will be collected and repeated at 1 hour intervals for 4 measurements to determine the aqueous flow rate (Ft). Following each set of scans, IOP will be measured using pneumatonometry (Model 30 Classic, Reichert Ophthalmic Instruments, Depew, New York). IOP will be recorded as the arithmetic mean of a total of 12 measurements per eye: 3 measurements every hour alternating between eyes.
- Tonography Tonographic outflow facility (C) will be performed using an electronic Schiøtz tonographer (Model 720, Berkeley Bioengineering Inc, USA) at 10AM. The facility of outflow will be calculated from the rate of decay of intraocular pressure in the supine position during application of a recording Schiøtz tonometer over a period of 4 minutes with a standard 5.5 gram weight. The "R" values of the curve at every 30-second time point will be manually entered into the McLaren tonography computer program. The program fits a second-degree polynomial by least squares to the nine data points and determines the best-fit values for time 0 and time 4 minutes by extrapolation. Uveoscleral outflow will be calculated using the Goldmann's equation with an assumed episcleral venous of 8, 9, 10 or 11 mmHg. Ft is the rate of aqueous humor formation, C is the tonographic facility of outflow, IOP is the intraocular pressure, Pv is the episcleral venous pressure and Fu is the uveoscleral outflow. Ft = C (IOP-Pv) +Fu Fu = Ft-C (IOP-Pv) Only one randomly (Excel random number generator) chosen eye per participant will be included in the data analysis when both eyes fulfilled the inclusion criteria.
- Visual fields Quantitative automated perimetry is performed using the Humphrey Field Analyzer. Visual field testing is performed before tonometry, gonioscopy, or any other technique that could affect vision. A visual field should be attempted in any eye that has sufficient vision to permit finger counting at two feet. Eyes with poor central vision may have an intact, off-center island of vision which may be measured with perimetry.
A 24-2 threshold test is performed in all patients using a size III white stimulus. Visual field testing may be performed with the Swedish Interactive Thresholding Algorithm (SITA) or full threshold strategy, but the same testing strategy must be used throughout the duration of the study. The pupil diameter should be 3 mm or greater before visual field testing is undertaken, and this may require pharmacologic dilation. Standardized refraction is performed to determine the patient's distance refraction and best-corrected visual acuity prior to visual field testing. The age appropriate plus lens is added to the distance refraction. Patient education is provided, and the instrument is set up for the test. The technician should monitor the patient during testing. Visual fields are performed preoperatively (within one month of enrollment in the study) and annually thereafter. Copies of all visual fields are faxed to the Statistical Coordinating Center for evaluation.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Healthy volunteers | – | –healthy age matched with cases volunteers as controls |
| Uveitis with raised IOP | – | –Recurrent (> 5 attacks) idiopathic acute anterior uveitic with raised intraocular pressure |
| Uveitis with with normal IOP | – | –Recurrent (> 5 attacks) idiopathic acute anterior uveitic with normal intraocular pressure |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- 30 patients will be included from each of these three group of patients: 1) recurrent (> 5 attacks) idiopathic acute anterior uveitic with raised intraocular pressure; 2) recurrent (> 5 attacks) idiopathic acute anterior uveitic without raised intraocular pressure; 3) healthy age matched volunteers as controls.
Key inclusion criteria (4 listed)
- Patients with idiopathic recurrent anterior uveitis with or without raised IOP.
- Normal healthy subjects with no ocular problems (other than refractive error) and IOP at screening < 21mmHg.
- Age >18 years.
- Adequate cognitive function and ability to understand verbal and written information in English.
Key exclusion criteria (8 listed)
- Other secondary glaucomas including pigment dispersion syndrome and pseudoexfoliation.
- Normotensive glaucoma.
- Primary angle closure.
- Ocular trauma.
- Intraocular or keratorefractive surgery.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Facility of outflow
Time frame: day 1 only (study completion)
Tonographic outflow facility (C) will be performed using an electronic Schiøtz tonographer (Model 720, Berkeley Bioengineering Inc, USA) at 10AM
Rate of aqueous flow (measured by fluorophotometry).
Time frame: Four times during the morning through day 1 only (study completion)
Fluorophotometry will be performed in both eyes using a scanning ocular fluorophotometer from 9AM to 12PM (FM-2, Fluorotron Master Ocular Fluorophotometer; OcuMetrics, Mountain View, California). The aqueous turnover protocol will be used to calculate the aqueous flow rate. Duplicate or triplicate scans will be collected and repeated at 1 hour intervals for 4 measurements to determine the aqueous flow rate (Ft).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Aug 2017.
- Derived from this study: PubMed 32277009Ho H, Daas A, Ho J, Alaghband P, Galvis EA, de Antonio Ramirez A, Grassi P, Lim R, Lim KS. Intraocular pressure changes following topical ocular hypotensive medications washout. Br J Ophthalmol. 2021 Feb;105(2):205-209. doi: 10.1136/bjophthalmol-2019-315778. Epub 2020 Apr 10.
- Individual participant dataSharing planned: No. No plans to share IPD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
K Sheng l, MD principal investigator
Guy's and St Thomas NHS Foundation Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Uveitic Glaucoma and Anterior Uveitis, run by Guy's and St Thomas' NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Facility of outflow (time frame: day 1 only (study completion)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02765308, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Aug 2017; AzTrials last refreshed its copy on 30 Oct 2026.